TAP accepts and reviews partnering inquiries year round.
TAP collaborates with and makes equity investments in biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations and orphan indications.
- Click here to download the initial inquiry form
Send the completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead, Therapy Acceleration Program® (email@example.com)
How did TAP benefit Forty Seven?
Listen to what the Chief Medical Officer of Forty Seven, Chris Takimoto, has to say about TAP and the value created for his company.
Recently Forty Seven was acquired by Gilead Sciences for $4.9 Billion.
How did TAP benefit Stemline Therapeutics?
Listen to what the SVP of Corporate & Business Development of Stemline, Peter McDonald, has to say about TAP and the value created for his company.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Due Diligence Process
Each year, TAP reviews opportunities from approximately 80-100 biotech companies to identify those with the highest potential to change the standard of care. Funding only the most promising projects that have a clear path forward for patients, TAP only invests in several new projects annually, with an open partnering cycle all year long.
Diligence typically takes 3-6 months, but varies based on company responsiveness to LLS requests.